These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7493372)

  • 21. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
    Brenner PC; Rettig WJ; Sanz-Moncasi MP; Reuter V; Aprikian A; Old LJ; Fair WR; Garin-Chesa P
    J Urol; 1995 May; 153(5):1575-9. PubMed ID: 7536270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.
    Greiner JW; Guadagni F; Roselli M; Ullmann CD; Nieroda C; Schlom J
    Dis Colon Rectum; 1994 Feb; 37(2 Suppl):S100-5. PubMed ID: 8313780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of iodine-125 CC49 monoclonal antibody in patients with colon cancer.
    Cook CH; Hinkle GH; Thurston MO; Martin EW
    Cancer Biother Radiopharm; 1996 Dec; 11(6):415-22. PubMed ID: 10851502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe.
    McIntosh DG; Colcher D; Seemayer T; Smith ML
    Cancer Biother Radiopharm; 1997 Aug; 12(4):287-94. PubMed ID: 10851478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
    Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
    Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
    Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.
    Xiao J; Horst S; Hinkle G; Cao X; Kocak E; Fang J; Young D; Khazaeli M; Agnese D; Sun D; Martin E
    Cancer Biother Radiopharm; 2005 Feb; 20(1):16-26. PubMed ID: 15778575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
    Meredith RF; Khazaeli MB; Plott WE; Grizzle WE; Liu T; Schlom J; Russell CD; Wheeler RH; LoBuglio AF
    Clin Cancer Res; 1996 Nov; 2(11):1811-8. PubMed ID: 9816134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.
    Mariani G; Molea N; Bacciardi D; Boggi U; Fornaciari G; Campani D; Salvadori PA; Giulianotti PC; Mosca F; Gold DV
    Cancer Res; 1995 Dec; 55(23 Suppl):5911s-5915s. PubMed ID: 7493369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.
    Guadagni F; Schlom J; Johnston WW; Szpak CA; Goldstein D; Smalley R; Simpson JF; Borden EC; Pestka S; Greiner JW
    J Natl Cancer Inst; 1989 Apr; 81(7):502-12. PubMed ID: 2466127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.
    Divgi CR; Scott AM; McDermott K; Fallone PS; Hilton S; Siler K; Carmichael N; Daghighian F; Finn RD; Cohen AM
    Nucl Med Biol; 1994 Jan; 21(1):9-15. PubMed ID: 9234259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients.
    Gallinger S; Reilly RM; Kirsh JC; Odze RD; Schmocker BJ; Hay K; Polihronis J; Damani MT; Shpitz B; Stern HS
    Cancer Res; 1993 Jan; 53(2):271-8. PubMed ID: 8417820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
    Shen S; Forero A; Meredith RF; LoBuglio AF
    Cancer Biother Radiopharm; 2011 Feb; 26(1):127-33. PubMed ID: 21355784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
    Shih LB; Xuan H; Aninipot R; Stein R; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.
    Mahvi DM; Madsen JA; Witt PL; Sondel PM
    Cancer Immunol Immunother; 1995 May; 40(5):311-4. PubMed ID: 7600563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A CDR-grafted (humanized) domain-deleted antitumor antibody.
    Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
    Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.